First things first, lets just try to get this to a 100 million market cap. NYC presentation monday followed by new CEO coming on late next week. Really hoping for trial details, academic institution, parameters, potential fast tracking, etc by the end of March.
Huge market here and my cost basis is incredibly low again this go around so I don't spend a lot of time on whether this is a billion or 10 billion dollar company. What I will say is how ingenious it was to go with the severe market first. It took balls to tackle a problem no one else can hope to solve and Alkon is still standing. The lack of a real competitor and the devastation of this disease will make this a much easier and quicker route to go towards approval and then every Alz patient in the world will want the drug. While others are having to re-do trials and guess how many of their patients actually even have the disease and while others hoping to show specific bio markers, Alkon is marching straight forward into a confirmatory trial. IF it shows the same promise we'll be a 500+ market cap company minimum and a lot of eyes will be on this MOA to see just how the FDA handles this going forward. The blogger doubters won't be able to spin that.
News 
Market Data 
Discover 
